Henry Ford Cancer Institute is First in the World to Activate Two New Treatments in GBM AGILE Trial for Glioblastoma

Henry Ford Cancer Institute is the first site in the world to activate two new treatments for glioblastoma (GBM), the deadliest form of brain cancer, as part of a patient-centered adaptive platform trial known as GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment).

International Research Team Confirms Potential Glioblastoma Inhibitors

However, San Diego Supercomputer Center (SDSC) Research Scientist Igor Tsigelny recently collaborated Researchers from the San Diego Supercomputer at UC San Diego and colleagues from Sweden’s Karolinska Institute and the Pasteur Institute in France released a study focused on improving the prognosis for glioblastoma patients.